Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eitan Kerem, Michael Wilschanski, Nilsen L

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Pulmonary exacerbations in CF patients with early lung disease

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Influence of digital clubbing on oxygen saturation measurements by pulse-oximetry in cystic fibrosis patients Filip Van Ginderdeuren, Karlien Van Cauwelaert,

Laboratory parameter profiles among patients with cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Nasal polyposis in lung transplant recipients with cystic fibrosis

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis Joseph M. Collaco, Karen S. Raraigh, Lawrence.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage Luke J. Berry, Barbara Sheil, Luke Garratt,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis Malena Cohen-Cymberknoh, Hannah Blau, David Shoseyov,

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan, Joseph M. Pilewski, Eitan Kerem, Ruth Tal-Singer, Aili L. Lazaar Journal of Cystic Fibrosis Volume 12, Issue 3, Pages 241-248 (May 2013) DOI: 10.1016/j.jcf.2012.08.016 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study schematic. Journal of Cystic Fibrosis 2013 12, 241-248DOI: (10.1016/j.jcf.2012.08.016) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 The effect of SB-656933 on sputum biomarkers at Day 28. Left: adjusted geometric mean±90% CI of the ratio to baseline for neutrophil numbers (top), neutrophil elastase (middle) and myeloperoxidase (bottom). —placebo, —SB-656933 20mg, —SB-656933 50mg. Right: adjusted geometric mean±90% CI for treatment ratio to placebo for SB-656933 20mg () and SB-656933 50mg (). Journal of Cystic Fibrosis 2013 12, 241-248DOI: (10.1016/j.jcf.2012.08.016) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 The effect of SB-656933 on blood biomarkers at Day 14 and Day 28. Left: adjusted geometric mean±90% CI of the ratio to baseline for fibrinogen (top), C-reactive protein (middle) and CXCL8 (bottom). —placebo, —SB-656933 20mg, —SB-656933 50mg. Right: adjusted geometric mean±90% CI for treatment ratio to placebo for SB-656933 20mg () and SB-656933 50mg (). Journal of Cystic Fibrosis 2013 12, 241-248DOI: (10.1016/j.jcf.2012.08.016) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions